Breakthrough designation for Boehringer's volasertib

Boehringer Ingelheim GmbH (Ingelheim, Germany) said FDA granted breakthrough therapy designation to volasertib to treat previously untreated acute myelogenous leukemia (AML) in patients ages 65 years or older who are ineligible for intensive remission induction therapy. The polo-like kinase 1 ( PLK1; STPK13) inhibitor is in the Phase III POLO-AML-2 trial in combination with low-dose cytarabine (LDAC) for the indication. ...